Co-Authors
This is a "connection" page, showing publications co-authored by Mariangela Manfredi and Arianna Damiani.
Connection Strength
1.118
-
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al. Ann Rheum Dis. 2020 Aug 04.
Score: 0.224
-
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD. Ann Rheum Dis. 2020 Jul 06.
Score: 0.223
-
COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. J Med Virol. 2020 11; 92(11):2368-2370.
Score: 0.222
-
Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr Med Assoc J. 2020 04; 22(4):203-210.
Score: 0.219
-
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli et al. Ann Rheum Dis. 2021 10; 80(10):e166.
Score: 0.060
-
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab. Immunol Res. 2021 08; 69(4):309-311.
Score: 0.060
-
Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies. J Med Virol. 2021 03; 93(3):1436-1442.
Score: 0.056
-
Old and new antirheumatic drugs for the treatment of COVID-19. Joint Bone Spine. 2020 05; 87(3):195-197.
Score: 0.055